In total , 247 noncarriers of a CYP2C19 * 2 loss-of-function allele were to receive 75 and 150 mg daily of clopidogrel ( 2 periods each ) , whereas 86 carriers ( 80 heterozygotes , 6 homozygotes ) were to receive 75 , 150 , 225 , and 300 mg daily .